ONE KENDALL SQUARE, CAMBRIDGE, MA
Initiates GLP Toxicology Studies for CMP-SYNGAP-01
Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
Earnings Release
Shareholder votes
Investor Presentation
Reports First Quarter 2025 Financial Results and Corporate Highlights
Annual Report to Security Holders
Reports Full Year 2024 Financial Results and Provides Corporate Update
Q2
Q1
FY 2024
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Certificate
Registration of Securities
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership